PET-CT imaging is a combination of metabolic, molecular, anatomical and structural imaging. Whilst conventional CT and MRI focuses more on anatomical and structural information, PET-CT imaging provides additional information regarding the metabolic and molecular changes that occur as a result of a disease process
Currently the following PET radiotracers are offered at Advanced Medicine Imaging:
FDG is the most commonly utilized radiotracer in PET-CT imaging.
Increase glucose utilization is seen in many disease processes,
for example, cancer, infection and inflammatory conditions.
Certain conditions can result in a decreased glucose metabolism,
for example, neurodegenerative disorders (eg, Alzheimer’s disease).
MIP image of a normal FDG PET-CT scan. Normal uptake is noted in the brain and urinary tract.
MIP and fusion images clearly depicting the extent and site of metastatic disease. Arrows on the fusion images point to metastatic disease in the lymph nodes, lung, pancreas, bone and soft tissue.
Acetate PET-CT has been utilized in different types of cancer eg, renal cell
neoplasm, myeloma, prostate cancer and hepatocellular carcinoma (HCC). In our centre,
Acetate PET-CT is used mainly in the evaluation of hepatocellular carcinoma (HCC). This
is sometimes performed in conjunction with a FDG PET-CT.
Acetate PET-CT usually detects the less aggressive well differentiated tumor whilst FDG PET-CT detects
the more aggressive less differentiated tumor components. This dual tracer approach helps identify
the different tumor clones as well as in improving lesion detection.
Fusion Acetate and FDG PET-CT images of a patient with a hepatocellular carcinoma (HCC).
Note the presence of moderate to intense uptake on the Acetate PET-CT and minimal uptake on the FDG PET-CT,
typical for a well differentiated HCC.
68 Gallium-PSMA PET-CT
PSMA is a transmembrane protein over expressed in approximately 90% of prostate cancers.
This radiotracer is commonly utilized and is the most accurate imaging agent currently available
for the staging, restaging and response assessment of prostate cancer. PSMA PET-CT is also used
in the work-up of patients prior to 177Lu-PSMA radionuclide therapy
MIP image of a normal PSMA PET-CT scan. Normal uptake is noted in the lacrimal, salivary glands, liver, spleen, bowel and urinary tract.
MIP and fusion images above clearly depicting the extent and site of metastatic disease in a patient with prostate cancer. Arrows on the fusion images point to metastatic disease in the lymph nodes and bone.
68 Gallium-Dotatate PET-CT
Ga-68 Dotatate is a PET radiotracer that has high affinity for type 2 somatostatin receptors (SSTR).
Certain cancers, for example well differentiated neuro-endocrine tumors, paragangliomas, meningiomas
and mesenchymal tumors express type 2 SSTRs and can be imaged on DOTATATE PET-CT.
MIP image of a normal DOTATATE PET-CT scan. Normal uptake is noted in the pituitary gland, liver, spleen, bowel and urinary tract.
MIP and fusion images clearly depicting the extent and site of disease in a patient with a small bowel neuroendocrine tumor. Arrows on the fusion images point to the primary tumor within the 3rd part of the duodenum and metastatic disease in the bone.
18F-Fluoroethyltyrosine (FET) PET-CT
18F-Fluoroethyltyrosine (FET) is an amino acid radiotracer which enter cells via the system L amino acid
transporter. It is mainly used in brain tumor imaging as an adjunct to MRI. It aids in identifying tumor
extent, in guiding biopsy as well as in treatment monitoring.
The FET-PET image clearly depicts the location and extent of the primary brain tumor which is otherwise not clearly identified on conventional T2w and post contrast T1w MRI images.
For more details, please contact Advanced Medicine Imaging at 6708-7888 or email firstname.lastname@example.org. We will be happy to assist you further.